{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:38:10Z","timestamp":1790523490890,"version":"4.1.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211214","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T20:59:24Z","timestamp":1548277164000},"page":"e0211214","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-5820","authenticated-orcid":true,"given":"Diane C.","family":"Broussou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Louis","family":"Toutain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Woehrl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"El Garch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bousquet-Melou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6629-1088","authenticated-orcid":true,"given":"Aude A.","family":"Ferran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/CMR.1.2.139","article-title":"Antibiotic combinations: should they be tested?","volume":"1","author":"GM Eliopoulos","year":"1988","journal-title":"Clin Microbiol Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1086\/605572","article-title":"Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"49","author":"S Deresinski","year":"2009","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref3","unstructured":"Clinical and Laboratory Standards Institute. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests f or Bacteria That Grow Aerobically; Approved Standard\u2014Ninth Edition. CLSI document M07-A9. Clinical and Laboratory Standards Institute; 2012."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"FC Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2014.03.002","article-title":"Evaluation of the best method to assess antibiotic potentiation by phytochemicals against Staphylococcus aureus","volume":"79","author":"AC Abreu","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fphar.2017.00553","article-title":"Synergistic Effect of Pleuromutilins with Other Antimicrobial Agents againstStaphylococcus aureus In Vitro and in an Experimental Galleria mellonella Model","volume":"8","author":"C-L Dong","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","article-title":"Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test","volume":"40","author":"RL White","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/ijmm.IJMM_17_189","article-title":"An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies","volume":"35","author":"S Laishram","year":"2017","journal-title":"Indian J Med Microbiol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1574-6976.2011.00295.x","article-title":"Emergence and spread of antibiotic resistance following exposure to antibiotics","volume":"35","author":"R Cant\u00f3n","year":"2011","journal-title":"FEMS Microbiol Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jac\/dkl387","article-title":"Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model","volume":"58","author":"AA Firsov","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref11","article-title":"The Hollow Fiber Infection Model: Principles and Practice","volume":"1","author":"JS Cadwell","year":"2015","journal-title":"Adv Antibiotics Antibodies"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1128\/AAC.01009-08","article-title":"Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model","volume":"53","author":"WE Rose","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"KL LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/cis473","article-title":"Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability","volume":"55","author":"JM Buyck","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkr450","article-title":"Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy","volume":"67","author":"FK Gould","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1469-0691.1998.tb00349.x","article-title":"In vitro activity of vancomycin combined with rifampin, amikacin, ciprofloxacin or imipenem against methicillin-resistant and methicillin-susceptible Staphylococcus aureus","author":"F Cok\u00e7a","year":"1998","journal-title":"Clinical Microbiology and Infection"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40268-016-0165-5","article-title":"Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen","volume":"17","author":"H Kato","year":"2017","journal-title":"Drugs RD"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/AAC.05664-11","article-title":"Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model","volume":"56","author":"AM Nicasio","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2003.07.001","article-title":"Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers","volume":"23","author":"G Adamis","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","article-title":"Clinical Pharmacokinetics of Vancomycin","volume":"11","author":"GR Matzke","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir078","article-title":"Vancomycin: We Can\u2019t Get There From Here","volume":"52","author":"N Patel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.01674-10","article-title":"Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding","volume":"55","author":"JM Butterfield","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0924-8579(02)00024-9","article-title":"Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations","volume":"19","author":"P Liu","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"R G\u00e1lvez","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"ref25","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"LA Mandell","year":"2007","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3389\/fmicb.2018.00572","article-title":"Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model","volume":"9","author":"DC Broussou","year":"2018","journal-title":"Front Microbiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin Pharmacokinetics\/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model","volume":"60","author":"BE Ferro","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref28","unstructured":"The European Comittee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0 [Internet]. 2018. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eucast.org\/clinical_breakpoints\/\" xlink:type=\"simple\">http:\/\/www.eucast.org\/clinical_breakpoints\/<\/ext-link>."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.44.9.2276-2285.2000","article-title":"Contribution of a Thickened Cell Wall and Its Glutamine Nonamidated Component to the Vancomycin Resistance Expressed by Staphylococcus aureus Mu50","volume":"44","author":"L Cui","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.00762-08","article-title":"Rapid Depletion of Free Vancomycin in Medium in the Presence of \u03b2-Lactam Antibiotics and Growth Restoration in Staphylococcus aureus Strains with \u03b2-Lactam-Induced Vancomycin Resistance","volume":"53","author":"C Yanagisawa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10096-005-0011-0","article-title":"Rapid decrease of free vancomycin in dense staphylococcal cultures","volume":"24","author":"C Ekdahl","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/jb.179.8.2557-2566.1997","article-title":"Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus","volume":"179","author":"K Sieradzki","year":"1997","journal-title":"J Bacteriol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"RD Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0034-5288(02)00039-5","article-title":"The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics","volume":"73","author":"PL Toutain","year":"2002","journal-title":"Res Vet Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1128\/AAC.38.9.2034","article-title":"Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis","volume":"38","author":"BJ McGrath","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"KL LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/cid\/civ426","article-title":"Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm","volume":"61","author":"T Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1875-9114.1997.tb03063.x","article-title":"Aminoglycoside Adaptive Resistance","volume":"17","author":"JA Karlowsky","year":"1997","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/jac\/dks522","article-title":"Cell wall thickening is associated with adaptive resistance to amikacin in methicillin-resistant Staphylococcus aureus clinical isolates","volume":"68","author":"W Yuan","year":"2013","journal-title":"J Antimicrob Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T08:23:38Z","timestamp":1720945418000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211214"}},"subtitle":[],"editor":[{"given":"Karsten","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211214","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]}}}